Dupont Capital Management Corp Alkermes Plc. Transaction History

Dupont Capital Management Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$28.34 - $33.63 $66,315 - $78,694	2,340 Added 131.53%	4,119 $128,000
Q1 2023 Apr 28, 2023	SELL	$25.31 - $29.02 $301,239 - $345,396	-11,902 Reduced 87.0%	1,779 $50,000
Q4 2022 Jan 26, 2023	BUY	$21.94 - $26.24 $19,241 - $23,012	877 Added 6.85%	13,681 $0
Q3 2022 Oct 31, 2022	SELL	$22.0 - $31.87 $169,928 - $246,163	-7,724 Reduced 37.63%	12,804 $286,000
Q2 2022 Jul 26, 2022	SELL	$26.4 - $30.54 $20,565 - $23,790	-779 Reduced 3.66%	20,528 $612,000
Q1 2022 Apr 27, 2022	SELL	$23.07 - $27.99 $43,486 - $52,761	-1,885 Reduced 8.13%	21,307 $561,000
Q4 2021 Jan 31, 2022	SELL	$21.47 - $32.08 $507,744 - $758,659	-23,649 Reduced 50.49%	23,192 $539,000
Q3 2021 Nov 03, 2021	BUY	$23.37 - $32.13 $229,423 - $315,420	9,817 Added 26.52%	46,841 $1.45 Million
Q2 2021 Jul 30, 2021	BUY	$18.78 - $25.15 $695,310 - $931,153	37,024 New	37,024 $908,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.